Celularity Inc. Depreciation and Amortization
Celularity Inc. (CELU) reported Depreciation and Amortization of $7.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-04-30
- Celularity Inc. depreciation, depletion and amortization for the quarter ending 2025-12-31 was $1.80M, a 3.89% decline year-over-year.
- Celularity Inc. depreciation, depletion and amortization for the quarter ending 2025-09-30 was $1.82M, a 3.70% decline year-over-year.
- Celularity Inc. depreciation, depletion and amortization for the quarter ending 2025-06-30 was $1.83M, a 8.12% decline year-over-year.
- Celularity Inc. depreciation, depletion and amortization for the quarter ending 2025-03-31 was $1.83M, a 14.94% decline year-over-year.
- Celularity Inc. depreciation, depletion and amortization for fiscal 2025 was $7.29M, a 7.91% decline from fiscal 2024.
- Celularity Inc. depreciation, depletion and amortization for fiscal 2024 was $7.92M, a 15.04% decline from fiscal 2023.
- Celularity Inc. depreciation, depletion and amortization for fiscal 2023 was $9.32M, a 1.19% decline from fiscal 2022.
- Celularity Inc. depreciation, depletion and amortization for fiscal 2022 was $9.44M, a 7.02% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $3.63M derived: sum of 2 quarters · filed 2026-04-30 | $5.46M derived: sum of 3 quarters · filed 2026-04-30 | $7.29M 10-K · filed 2026-04-30 |
| 2025-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.66M derived: sum of 2 quarters · filed 2025-11-14 | $5.49M 10-Q · filed 2025-11-14 | $7.37M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $3.67M 10-Q · filed 2025-08-29 | $5.54M derived: sum of 3 quarters · filed 2026-04-30 | $7.44M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $1.83M 10-Q · filed 2025-08-29 | $3.71M derived: sum of 2 quarters · filed 2026-04-30 | $5.60M derived: sum of 3 quarters · filed 2026-04-30 | $7.60M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $3.77M derived: sum of 2 quarters · filed 2026-04-30 | $5.77M derived: sum of 3 quarters · filed 2026-04-30 | $7.92M 10-K · filed 2026-04-30 |
| 2024-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.89M derived: sum of 2 quarters · filed 2025-11-14 | $6.05M 10-Q · filed 2025-11-14 | $8.34M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $4.15M 10-Q · filed 2025-08-29 | $6.45M derived: sum of 3 quarters · filed 2025-08-29 | $8.79M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $2.16M 10-Q · filed 2025-08-29 | $4.45M derived: sum of 2 quarters · filed 2025-08-29 | $6.79M derived: sum of 3 quarters · filed 2025-08-29 | $9.12M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $4.64M derived: sum of 2 quarters · filed 2025-05-08 | $6.96M derived: sum of 3 quarters · filed 2025-05-08 | $9.32M 10-K · filed 2025-05-08 |
| 2023-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $4.67M derived: sum of 2 quarters · filed 2024-12-06 | $7.03M 10-Q · filed 2024-12-06 | $9.47M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $4.68M 10-Q · filed 2024-11-07 | $7.12M derived: sum of 3 quarters · filed 2024-11-07 | $9.52M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $2.36M 10-Q · filed 2024-10-16 | $4.80M derived: sum of 2 quarters · filed 2024-10-16 | $7.20M derived: sum of 3 quarters · filed 2024-10-16 | $9.52M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $4.83M derived: sum of 2 quarters · filed 2024-07-30 | $7.15M derived: sum of 3 quarters · filed 2024-07-30 | $9.44M 10-K · filed 2024-07-30 |
| 2022-09-30 | $2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $4.71M derived: sum of 2 quarters · filed 2024-01-03 | $7.00M 10-Q · filed 2024-01-03 | $9.60M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.60M 10-Q · filed 2023-08-14 | $7.21M derived: sum of 3 quarters · filed 2023-08-14 | $9.55M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $2.28M 10-Q · filed 2023-05-22 | $4.89M derived: sum of 2 quarters · filed 2023-05-22 | $7.23M derived: sum of 3 quarters · filed 2023-05-22 | $9.16M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $4.95M derived: sum of 2 quarters · filed 2023-03-31 | $6.88M derived: sum of 3 quarters · filed 2023-03-31 | $8.82M 10-K · filed 2023-03-31 |
| 2021-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $4.28M derived: sum of 2 quarters · filed 2022-11-10 | $6.21M 10-Q · filed 2022-11-10 | $8.04M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.87M 10-Q · filed 2022-08-09 | $5.70M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $1.94M 10-Q · filed 2022-05-16 | $3.77M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $8.17M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $6.34M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |